<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04272762</url>
  </required_header>
  <id_info>
    <org_study_id>274347</org_study_id>
    <nct_id>NCT04272762</nct_id>
  </id_info>
  <brief_title>Catheter Ablation in Symptomatic Atrial Fibrillation</brief_title>
  <official_title>Catheter Ablation in Symptomatic Atrial Fibrillation: a Double Blind Randomised Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>East Sussex Hospitals NHS Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eastbourne Cardiology Research Charity Fund</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>East Sussex Hospitals NHS Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a double blinded randomised placebo-controlled trial comparing the effects of
      catheter ablation (Cryoablation) versus a placebo procedure on atrial fibrillation burden,
      symptoms and quality of life
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 23, 2020</start_date>
  <completion_date type="Anticipated">June 2021</completion_date>
  <primary_completion_date type="Anticipated">June 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Atrial fibrillation burden using continuous monitoring</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to symptomatic atrial tachyarrhythmia stratified by length of episode</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to asymptomatic atrial tachyarrhythmia stratified by length of episode</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of atrial arrhythmia ( symptomatic and asymptomatic) episodes stratified by length of episode</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in AF specific quality of life score between each group (AF-PROMS)</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in health related quality of life in each group (36-Item Short Form Survey Instrument )</measure>
    <time_frame>Baseline and 6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of medical treatment ( Antiarrhythmic drug use)</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Comparison of unscheduled use of health care services</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of procedure related complications / adverse events</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">140</enrollment>
  <condition>Atrial Fibrillation</condition>
  <arm_group>
    <arm_group_label>Ablation</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>pulmonary vein isolation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo procedure</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cryoablation</intervention_name>
    <description>Pulmonary vein isolation with cryoablation</description>
    <arm_group_label>Ablation</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo procedure</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age greater than or equal to 18 years

          -  Symptomatic paroxysmal or persistent atrial fibrillation despite at least one
             antiarrhythmic drug (AAD Type I or III, β-blocker or AAD intolerance).

          -  Referred for catheter ablation

        Exclusion Criteria:

          -  Long term persistent AF (continuous episode lasting more than 1)

          -  Prior left atrium catheter or surgical atrial fibrillation ablation

          -  Patients with other arrhythmias requiring ablative therapy

          -  Left atrium (LA) ≥5.5 cm

          -  Any cardiac surgery or percutaneous coronary intervention (PCI) within three months
             prior to enrolment.

          -  Awaiting cardiac surgery or PCI

          -  Myocardial infarction within three months prior to enrolment.

          -  Stroke or transient ischemic attack (TIA) within three months prior to enrolment

          -  Unstable angina

          -  Any significant congenital heart defect corrected or not (including atrial septal
             defects or PV abnormalities) but not including patent foramen ovale.

          -  Any condition contraindicating chronic anticoagulation

          -  Any untreated or uncontrolled hyperthyroidism or hypothyroidism

          -  Severe chronic kidney disease (stage V, requiring or almost requiring dialysis,
             glomerular filtration rate (GFR) &lt; 15 ml / min)

          -  Patients with metallic prosthetic valves

          -  Pregnant or breastfeeding women

          -  Medical conditions limiting expected survival to &lt;1 year

          -  History of claustrophobia or panic attacks
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Rick Veasey</last_name>
    <phone>0300 131 4500</phone>
    <phone_ext>4132</phone_ext>
    <email>rick.veasey@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Rajdip Dulai</last_name>
    <phone>0300 131 4500</phone>
    <phone_ext>4132</phone_ext>
    <email>rajdip.dulai@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Eastbourne District General Hospital</name>
      <address>
        <city>Eastbourne</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rick Veasey</last_name>
      <email>rick.veasey@nhs.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Conquest Hospital</name>
      <address>
        <city>St Leonards-on-Sea</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stephen Furniss</last_name>
      <email>sfurniss@nhs.net</email>
    </contact>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2020</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 14, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>February 14, 2020</last_update_submitted>
  <last_update_submitted_qc>February 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">February 17, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>East Sussex Hospitals NHS Trust</investigator_affiliation>
    <investigator_full_name>Rick Veasey</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Ablation</keyword>
  <keyword>Cryoablation</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

